

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listing of claims in the application. The following amendments are without prejudice and do not constitute an admission regarding the patentability of the amended subject matter and should not be so construed. Applicant reserves the right to pursue the subject matter of the canceled claims in this or any other appropriate patent application.

**Complete Listing of Claims:**

Claims 1 – 236. (Cancelled)

Claim 237. (New) A pharmaceutical composition for oral administration in a solid dosage form comprising:

- (a) about 5 mg to about 100 mg of non-enteric coated omeprazole;
- (b) a buffer comprising at least about 250 mg sodium bicarbonate; and
- (c) about 12 mg to about 66 mg of a disintegrant.

Claim 238. (New) The composition of claim 237, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 239. (New) The pharmaceutical composition of claim 237, wherein the disintegrant is croscarmellose sodium.

Claim 240. (New) The composition of claim 239, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 241. (New) The pharmaceutical composition of claim 237, wherein the buffer is present in an amount of about 36 wt-% to about 97 wt-%.

Claim 242. (New) The composition of claim 237, further comprising enteric coated omeprazole.

Claim 243. (New) The composition of claim 240, wherein the omeprazole is present in the composition in an amount of about 20 mg.

Claim 244. (New) The composition of claim 240, wherein the omeprazole is present in the composition in an amount of about 40 mg.

Claim 245. (New) The composition of claim 240, further comprising at least one pharmaceutically acceptable excipient selected from the group consisting of a binder, a lubricant, and a parietal cell activator.

Claim 246. (New) The composition of claim 237, wherein the buffer further comprises at least one additional buffering agent.

Claim 247. (New) The composition of claim 246, wherein the at least one additional buffering agent is selected from magnesium hydroxide, calcium carbonate or magnesium oxide.

Claim 248. (New) The composition of claim 237, wherein the buffer is sodium bicarbonate.

Claim 249. (New) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 10 mEq to about 70 mEq.

Claim 250. (New) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 7 mEq to about 25 mEq.

Claim 251. (New) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 20 mEq to about 40 mEq.

Claim 252. (New) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 4 mEq to about 30 mEq.

Claim 253. (New) The composition of claim 237, wherein the solid dosage form is non-enteric coated.

Claim 254. (New) A pharmaceutical composition for oral administration in a solid dosage form comprising:

- (a) about 15mg to about 80 mg of non-enteric coated omeprazole or an isomer of omeprazole, or an ester, amide, free base or salt thereof;
- (b) about 56 wt-% to about 97 wt-% of a buffer; and
- (c) about 1.3 wt-% to about 3.8 wt-% of a disintegrant.

Claim 255. (New) The composition of claim 254, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 256. (New) The pharmaceutical composition of claim 255, wherein the disintegrant is croscarmellose sodium.

Claim 257. (New) The composition of claim 254, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 258. (New) The pharmaceutical composition of claim 254, wherein the omeprazole is present in an amount of about 1.2-2.9 wt-%.

Claim 259. (New) The composition of claim 254, further comprising enteric coated omeprazole.

Claim 260. (New) The composition of claim 255, wherein the omeprazole is present in the composition in an amount of about 20 mg.

Claim 261. (New) The composition of claim 255, wherein the omeprazole is present in the composition in an amount of about 40 mg.

Claim 262. (New) The composition of claim 255, further comprising at least one pharmaceutically acceptable excipient selected from the group consisting of a binder, a lubricant, and a parietal cell activator.

Claim 263. (New) The composition of claim 254, wherein the buffer further comprises at least one additional buffering agent.

Claim 264. (New) The composition of claim 26, wherein the at least one additional buffering agent is selected from magnesium hydroxide, calcium carbonate or magnesium oxide.

Claim 265. (New) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 250 mg to about 4000 mg.

Claim 266. (New) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 10 mEq to about 70 mEq.

Claim 267. (New) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 7 mEq to about 25 mEq.

Claim 268. (New) The composition of claim 254, wherein the magnesium hydroxide is present in the composition in a total amount of about 20 mEq to about 40 mEq.

Claim 269. (New) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 4 mEq to about 30 mEq.

Claim 270. (New) The composition of claim 254, wherein the solid dosage form is non-enteric coated.

Claim 271. (New) The composition of claim 254, wherein at least some of the omeprazole is micronized.

Claim 272. (New) The composition of claim 237, wherein at least some of the omeprazole is micronized.

Claim 273. (New) A solid oral pharmaceutical composition comprising:

(a) non-enteric coated omeprazole in an amount of about 2 mg to about 100 mg; and

(b) a buffer comprising about 0.375 mEq to about 0.75 mEq of sodium bicarbonate per mg of omeprazole;

wherein the buffer is present in the solid oral pharmaceutical composition in an amount sufficient to permit absorption of a therapeutically effective amount of the non-enteric coated omeprazole after oral administration to a subject.

Claim 274. (New) The solid oral pharmaceutical composition of claim 273, wherein the omeprazole is present in an amount of about 20 mg.

Claim 275. (New) The solid oral pharmaceutical composition of claim 273, wherein the omeprazole is present in an amount of about 40 mg.

Claim 276. (New) The solid oral pharmaceutical composition of claim 273, wherein said solid oral pharmaceutical composition is in a dosage form selected from the group consisting of a tablet, a capsule, an effervescent powder, pellets and granules.

Claim 277. (New) The solid oral pharmaceutical composition of claim 276, wherein the dosage form is a capsule.

Claim 278. (New) The solid oral pharmaceutical composition of claim 276, wherein the dosage form is a tablet.

Claim 279. (New) The solid oral pharmaceutical composition of claim 273, wherein the buffer is sodium bicarbonate.

Claim 280. (New) The solid oral pharmaceutical composition of claim 273, wherein the omeprazole is micronized.